interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Eluxadoline

Generic competition · all medicines · read 12 November 2026

Is there a generic of Eluxadoline, and who makes it?

Eluxadoline appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 9.8 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Eluxadoline1 dosage-form group in the Orange Book
0generic makers listed
  1. Eluxadoline appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 9.8 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Viberzi. No generic is listed as marketed (4 generic products listed as discontinued).

2015202020252030203501brand 2015data datePatent 9115091 listed to expire 7 July 2028Patent 9364489 listed to expire 7 July 2028Patent 9789125 listed to expire 7 July 2028Patent 8691860 listed to expire 7 July 2028Patent 7741356 listed to expire 27 May 2029Patent 12097187 listed to expire 14 March 2033Patent 11007179 listed to expire 14 March 2033Patent 11311516 listed to expire 14 March 2033Patent 9675587 listed to expire 14 March 2033Patent 11229627 listed to expire 14 March 2033Patent 11160792 listed to expire 14 March 2033Patent 10188632 listed to expire 14 March 2033Patent 11090291 listed to expire 14 March 2033Patent 11484527 listed to expire 14 March 2033
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 7 July 2028Patent 9115091 drug substance
  • 7 July 2028Patent 9364489
  • 7 July 2028Patent 9789125 drug product
  • 7 July 2028Patent 8691860 drug substance
  • 27 May 2029Patent 7741356 drug substance
  • 14 March 2033Patent 12097187
  • 14 March 2033Patent 11007179 drug product
  • 14 March 2033Patent 11311516 drug product

6 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.